Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Unknown 3Recruiting 2Completed 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 65NIH 18UNKNOWN 6OTHER_GOV 3INDUSTRY 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Oesophagogastric Cancer 1

Interventions

apatinib 25Cisplatin 19Capecitabine 17Irinotecan 16Cyclophosphamide 16fludarabine 14Radiotherapy 12Oxaliplatin 12Drug Therapy 12camrelizumab 11Paclitaxel 11S 1 (combination) 10Docetaxel 10Carboplatin 10Fluorouracil 9Blood Specimen Collection 9Bevacizumab 9Nivolumab 8tislelizumab 7Radiation 7Pemetrexed 7Gemcitabine 7Erlotinib Hydrochloride 7Surgical Procedures, Operative 6Neoadjuvant Therapy 6Albumin-Bound Paclitaxel 6toripalimab 5anlotinib 5XELOX 5Tamoxifen 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Epirubicin × Clear all
NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Henan Cancer Hospital

Phase 1/2 Unknown
39 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03755115 2019-01-16

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Henan Cancer Hospital

Phase 2 Unknown
40 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown
1,103 enrolled
Gastrointestinal

Oesophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡